|
TissueArray.com LLC
ffpe pdac tissue slides Ffpe Pdac Tissue Slides, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/ffpe+pdac+tissue+slides/bio_rxiv__2024__10__11__617879-306-0-16 Average 90 stars, based on 1 article reviews
ffpe pdac tissue slides - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Servicebio Inc
pdac tissue microarray Pdac Tissue Microarray, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/pdac+tissue+microarray/pm35288467-148-0-32 Average 90 stars, based on 1 article reviews
pdac tissue microarray - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Wolters Kluwer Health
human pdac tissues Human Pdac Tissues, supplied by Wolters Kluwer Health, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/human+pdac+tissues/10__1097_slash_mpa__0000000000000270-105-14-2 Average 90 stars, based on 1 article reviews
human pdac tissues - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Charles River Laboratories
human pdac tissue Human Pdac Tissue, supplied by Charles River Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/human+pdac+tissue/pm30203567-162-40-54 Average 90 stars, based on 1 article reviews
human pdac tissue - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
wt dhx9 protein ![]() Wt Dhx9 Protein, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/dhx9+protein+expression+in+pdac+tissues/med_rxiv__2023__03__01__23286475-211-0-7 Average 90 stars, based on 1 article reviews
wt dhx9 protein - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Servicebio Inc
pdac tissue array slides ![]() Pdac Tissue Array Slides, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/pdac+tissue+array+slides/pm38757623-287-1-15 Average 90 stars, based on 1 article reviews
pdac tissue array slides - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
U.S Biomax Inc
human pdac tissue sections ![]() Human Pdac Tissue Sections, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/human+pdac+tissues/pmc04860133-122-2-14 Average 90 stars, based on 1 article reviews
human pdac tissue sections - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Perthera Inc
pdac tissue blocks ![]() Pdac Tissue Blocks, supplied by Perthera Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/pdac+tissue+blocks/pm38642081-33-4-34 Average 90 stars, based on 1 article reviews
pdac tissue blocks - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Biomax Inc
pdac tissue microarrays biomax hpan-ade180sur-01 ![]() Pdac Tissue Microarrays Biomax Hpan Ade180sur 01, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/pdac+tissue+microarrays+biomax+hpan+ade180sur+01/pmc06154863-113-15-13 Average 90 stars, based on 1 article reviews
pdac tissue microarrays biomax hpan-ade180sur-01 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Human Protein Atlas
immunohistochemistry (ihc) staining of pdac patient tissues ![]() Immunohistochemistry (Ihc) Staining Of Pdac Patient Tissues, supplied by Human Protein Atlas, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/immunohistochemistry++ihc++staining+of+pdac+patient+tissues/pmc10814254-53-4-11 Average 90 stars, based on 1 article reviews
immunohistochemistry (ihc) staining of pdac patient tissues - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Servicebio Inc
paraffin-embedded pdac tissue arrays ![]() Paraffin Embedded Pdac Tissue Arrays, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/paraffin+embedded+pdac+tissue+arrays/pm40439109-30-7-1 Average 90 stars, based on 1 article reviews
paraffin-embedded pdac tissue arrays - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Eli Lilly
hpaf-ii kras mutant pdac rat xenograft tumor tissue ![]() Hpaf Ii Kras Mutant Pdac Rat Xenograft Tumor Tissue, supplied by Eli Lilly, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/pdac+tissue/hpaf+ii+kras+mutant+pdac+rat+xenograft+tumor+tissue/pmc07393480-36-0-11 Average 90 stars, based on 1 article reviews
hpaf-ii kras mutant pdac rat xenograft tumor tissue - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: (A) Relationship between pLoF and missense constraint among known or candidate DDX/DHX disease genes. Genes linked to dominant disease traits are shown in red, recessive traits in blue, and mixed dominant/recessive traits in orange. Solid line indicates linear regression. Dashed line shows top LOEUF decile. Y-axis, LOEUF; X-axis, missense Z-score (gnomAD v2.1.1). (B) Relationship between pLoF and missense constraint among all DDX/DHX disease genes. DHX9 is indicated by a red dot. Paralogs DHX30 and DDX3X are indicated by blue dots. Solid line indicates linear regression. Dashed line shows top LOEUF decile. Y-axis, LOEUF; X-axis, missense Z-score (gnomAD v2.1.1). (C) DHX9 mRNA expression in human adult tissues from the Genotype-Tissue Expression (GTEx) project. Nervous system tissues are highlighted in gray. Y-axis, TPM, transcripts per million. (D) Average mRNA expression of known or candidate DDX/DX disease genes in the developing nervous system from Brainspan. DHX9 is indicated by red dots. Paralogs DHX30 and DDX3X are indicated by blue dots. Y-axis, log2 RPKM, Reads Per Kilobase Million; X-axis, development stage, pcw = post-conception weeks, mo = months, yrs = years.
Article Snippet:
Techniques: Expressing
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: Pedigrees, DHX9 genotypes, and representative brain MRIs of patients with neurodevelopmental disorders (NDD) are shown above the black line. Patients, genotypes, and representative clinical images and leg muscle MRIs of patients with Charcot-Marie-Tooth disease are shown below the black line. Images of the proband’s feet from Family 15 are redacted per Medrxiv rules regarding identifiable characteristics/body parts but are available upon request from the corresponding author. Yellow arrow indicates thin corpus callosum. Red arrows indicate cerebellar atrophy. Yellow arrowheads show enlargement of the ventricles, and yellow asterisks (brain MRI, second image from right) show reduced white matter volume. Photograph shows pes cavus and hammer toe deformity in Family 15 with CMT. Yellow asterisks (leg MRI) highlight fatty infiltration of the lower leg musculature consistent with CMT. Black pedigree symbols indicate NDDs, whereas gray pedigree symbols indicate CMT.
Article Snippet:
Techniques:
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: (A) Diagram of DHX9 mRNA showing location of NDD-associated (white) and CMT-associated (black) variants. (B) Diagram of DHX9 protein showing functional domains including double-stranded RNA-binding domains (dsRBD1&2), minimal transactivation domain (MTAD), helicase domains, helicase associated domain 2 (HA2), oligonucleotide/oligosaccharide-binding fold (OB-fold), and the RGG box. Protein domains were obtained from Uniprot. The sequence of the nuclear localization signal is magnified and the two key residues Lys1163 and Arg1166 are underlined. DHX9’s protein tolerance landscape is shown below the figure as calculated by Metadome.
Article Snippet:
Techniques: Functional Assay, RNA Binding Assay, Binding Assay, Sequencing
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: (A) Gap statistic curve for DHX9 cohort. Gap statistic is displayed on the y axis and number of clusters tested on the x axis. The point on the curve where slope changed from a trend of higher to lower (i.e., additional clusters not adding as much to the gap statistic) was chosen as optimal number of clusters (k=4). (B) HAC and visualization of quantitative phenotypic similarity allow refinement of genotype-phenotype correlations in DHX9 cohort. The dendrogram shown at the top and to the left of the heatmap is based on HAC analysis of the dissimilarity matrix produced from Resnik semantic similarity scores and with k=4. Unique clusters are represented by different colors, and individual probands are labeled on top of and to the right of the heatmap. Within the heatmap, dark red indicates a higher similarity, while dark blue indicates lower similarity. A key is provided on the right. (C) Magnified dendrogram showing unique clusters and group characteristics.
Article Snippet:
Techniques: Produced, Labeling
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: (A) Subcellular localization of EGFP-tagged DHX9 WT protein, NLS p.K1163R (severe NDD), truncating p.R229* (mild NDD) and CMT p.A1255T mutant proteins expressed in MCF-7 and PC-3 human cells. Nucleolar loci were co-stained by the Fibrillarin (FBL) marker and DNA stained by DAPI. Scale bar = 10 µm. (B) Endogenous expression of DHX9 in fibroblasts from the severe NDD proband with the p.K1163R NLS variant and the unaffected father. Scale bar = 40 µm. (C) Staining of levels of R-loop formation by the S9.6 marker and DSB by the γ-H2AX marker in MCF-7 cells expressing WT or the p.R141Q mutant protein. Scale bar = 10 μm. See also Figure S5, S6.
Article Snippet:
Techniques: Mutagenesis, Staining, Marker, Expressing, Variant Assay
Journal: medRxiv
Article Title: Monoallelic variation in DHX9 , the gene encoding the DExH-box helicase DHX9, underlies neurodevelopment disorders and Charcot-Marie-Tooth disease
doi: 10.1101/2023.03.01.23286475
Figure Lengend Snippet: (A-C) Dhx9 -/- mice were hypoactive in response to a novel environment (decreased distance travelled (A) and speed (B)) in open field and decreased rearing (C) on first introduction to a novel home cage. However, male Dhx9 -/- mice showed more rearing activity with lights off during the active phase in the home cage. This increased vertical activity was evident in both male and female Dhx9 -/- in the latter half of the active phase. Shaded areas encompass period between lights off/lights on, 18:00-06:00, and are mean ± SEM. (D, E) Both 2-paw and 4-paw grip strength were reduced in Dhx9 -/- mice (D). Lower grip strength was predicted by the lower body weight in linear regression analysis (E). (E) Twenty per cent of Dhx9 -/- mice showed tremors in the SHIRPA analysis. G, H) Both absent auditory response curve in the auditory brainstem response (G) and decreased acoustic startle reactivity (H) indicated deafness in Dhx9 -/- mice. (I-K) The body weight of Dhx9 -/- mice was lower than wild-type mice (I). Dhx9 -/- mice had lower cumulative food intake and lost more weight over a 21 h period after transfer to a new home cage than wild-type mice. #p < 0.05, male +/+ vs. -/-, *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 +/+ vs. -/-. Data are mean ± SD.
Article Snippet:
Techniques: Activity Assay
Journal: Nature medicine
Article Title: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor progression
doi: 10.1038/nm.4082
Figure Lengend Snippet: ( a ) H&E and Trichrome (top insert) staining of PDAC tissue arrays for well ( n = 19), moderately ( n = 23) or poorly differentiated ( n = 26) tumors; Scale bar, 100 µm (main) and 50 µm (insert). Immunofluorescence images and quantifications of α-SMA, p-MLC2, p-SMAD2 and DAPI; Scale bar, 75 µm (main) and 40 µm (insert). Polarized light images of picrosirius red (PR) within the main stroma (MS) (3 rd ) and periductal stroma (DS) (3 rd insert); Scale bar, 50 µm (main) and 40 µm (insert). Second harmonic generation (SHG) of periductal collagen and diameter color-coded SHG; Scale bar, 75 µm. ( b ) H&E and Trichrome (top insert) staining of tissue from PDAC patients with a median short survival of 11–289 days ( n = 29) and median long survival of 1090–3298 days ( n = 28); Scale bar, 100 µm. Immunofluorescence and quantification of tissue stained for α-SMA, p-MLC2, p-SMAD2 and DAPI; Scale bar, 75 µm. PR staining within the main stroma (MS) and periductal stroma (DS) (insert); Scale bar, 50µm. Periductal SHG and diameter color-coded SHG; Scale bar, 75 µm. ( c ) H&E staining of PDAC tissue from wild type SMAD4 ( n = 10) and mutant SMAD4 ( n = 10) patients. Scale bar, 100 µm. PR staining and quantification within the main stroma (MS) and periductal stroma (DS); Scale bar, 50 µm. Force maps and quantification of the main stroma (MS) (insert) and periductal stroma (DS) (insert). SHG of periductal collagen and diameter color-coded SHG; Scale bar, 75 µm. Immunofluorescence staining and quantification for p-MLC2 and DAPI; Scale bar, 75 µm. Results are presented as the mean +/− SEM. Subsequent statistical analysis was performed with either unpaired two-sided student t-tests, one-way ANOVA with Tukey’s method for multiple comparisons. (* P < 0.05; ** P < 0.01, *** P < 0.001, **** P < 0.0001, “ns” not significant).
Article Snippet: Formalin-fixed, paraffin-embedded
Techniques: Staining, Immunofluorescence, Mutagenesis
Journal: Cancers
Article Title: Multi-Algorithm Analysis Reveals Pyroptosis-Linked Genes as Pancreatic Cancer Biomarkers
doi: 10.3390/cancers16020372
Figure Lengend Snippet: Elevated BHLHE40, IL18, BIRC3, and APOL1 in PDAC tumour samples and cell lines. ( A ) RT-qPCR results for BHLHE40, IL18, BIRC3, and APOL1 in PDAC cell lines MIA-PaCa2, BxPc-3, PANC-1, and AsPC-1 and the non-cancerous pancreatic ductal cell line CRL-4023. ( B ) The heatmap displays expression variations of these genes across the PDAC cell lines according to data extracted from the GEO database. ( C ) According to the Human Atlas Protein database, IHC of BHLHE40, IL18, BIRC3, and APOL1 in normal and PDAC tissue. ( D ) Quantitative presentation of IHC results. Data are graphed as the mean ± SD. ns, not significant; *, p < 0.05; **, p < 0.01; ***, p < 0.001.
Article Snippet: Immunohistochemistry (IHC) staining of
Techniques: Quantitative RT-PCR, Expressing
Journal: Cell reports
Article Title: Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
doi: 10.1016/j.celrep.2020.107764
Figure Lengend Snippet: (A) PDAC cell lines were infected by lentivirus vectors encoding nonspecific (NS) control or distinct shRNAs targeting ARAF, BRAF, CRAF, or KRAS sequences. Colonies were stained by crystal violet ~10 days after plating. Data are presented as median. All p values shown are in comparison to the vehicle control for the individual graph. Adjusted p values are from Dunnett’s multiple comparison test. Adjusted p values: Pa01C ( ARAF-sh1 = 0.6792, ARAF-sh2 = 0.6726, BRAF-sh1 = 0.8883, BRAF-sh2 = 0.0592, CRAF-sh1 = *, 0.0024, CRAF-sh2 = 0.6350), ( KRAS-sh = ***, 0.0010). Pa02C ( ARAF-sh1 = 0.7153, ARAF-sh2 = 0.0692, BRAF-sh1 = 0.8788, BRAF-sh2 = 0.1990, CRAF-sh1 = 0.0539, CRAF-sh2 = 0.2738), ( KRAS-sh = **, 0.0068). Pa14C ( ARAF-sh1 = ****, < 0.0001, ARAF-sh2 = ****, < 0.0001, BRAF-sh1 = *, 0.0103, BRAF-sh2 = ****, < 0.0001, CRAF-sh1 = ****, < 0.0001, CRAF-sh2 = ****, < 0.0001, KRAS-sh = ****, < 0.0001). Pa16C ( ARAF-sh1 = 0.9995, ARAF-sh2 = 0.7500, BRAF-sh1 = 0.9977, BRAF-sh2 = ****, < 0.0001, CRAF-sh1 = ****, < 0.0001, CRAF-sh2 = ****, < 0.0001, KRAS-sh = ****, < 0.0001). MIA PaCa-2 ( ARAF-sh1 = 0.5520, ARAF-sh2 = **, 0.0051, BRAF-sh1 = 0.2316, BRAF-sh2 = **, 0.0076, CRAF-sh1 = **, 0.0086, CRAF-sh2 = **, 0.0098). PANC-1 ( ARAF-sh1 = 0.3213, ARAF-sh2 = ****, < 0.0001, BRAF-sh1 = 0.0586, BRAF-sh2 = **, 0.0025, CRAF-sh1 = ****, < 0.0001, CRAF-sh2 = ****, < 0.0001). (B) PDAC cell lines were treated with RAFi (0.04–10 μM, 72 h). Cell lysates were immunoblotted to determine levels of the indicated proteins. Data are representative of three independent experiments. (C) PDAC cell lines were treated with RAFi (0.01–2.5 μM, 72 h). Proliferation was measured by Calcein AM cell viability assay. Data are the mean average of three independent experiments. Error bars are shown as ± SEM. (D) CRISPR screen. PDAC cell lines were infected with the CRISPR library and treated with vehicle control or RAFi (w2, 2 weeks; w4, 4 weeks; a and b indicate replicate samples). The enrichment score indicates either enrichment (red) or depletion (blue) of the indicated genes in cells treated with RAFi relative to vehicle control. (E) Cell lines were infected by lentivirus vectors encoding NS or two distinct ARAF shRNAs (72 h) and treated with RAFi (0.01–2.5 μM, 120 h). Proliferation was measured by Calcein AM cell viability assay. Data are the mean average of three technical replicates. Error bars are shown as ± SEM. Summary of GI 50 values.
Article Snippet:
Techniques: Infection, Control, Staining, Comparison, Viability Assay, CRISPR
Journal: Cell reports
Article Title: Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
doi: 10.1016/j.celrep.2020.107764
Figure Lengend Snippet: (A) RPPA analyses of PDAC cell lines treated with vehicle control, RAFi (0.3 μM), ERKi (0.04 μM), or the combination for multiple time points (0.25, 1, 8, 24 and 72 h). RAFi/ERKi-treated PDAC cells were normalized to their respective vehicle control. Proteins with significant phosphorylation or expression changes at 72-h time point are plotted as fold changes. Red, increased fold change; blue, decreased fold change; white, no change. (B) GSEA of the cell lines shown in (A). Enriched or depleted gene sets treated with RAFi/ERKi compared to RAFi (upper graph) or ERKi (below graph) are shown (24 h). (C) Pa16C cells were treated with vehicle control, RAFi (0.3 μM) and ERKi (0.04 μM) alone, or the combination (120 h). Cell lysates were immunoblotted to determine levels of pERK, total ERK, total MYC, and vinculin. Data are representative of three independent experiments.
Article Snippet:
Techniques: Control, Phospho-proteomics, Expressing
Journal: Cell reports
Article Title: Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
doi: 10.1016/j.celrep.2020.107764
Figure Lengend Snippet: (A) KRAS mutant cancer cell lines were treated with RAFi (0.01–2.5 μM) and ERKi (0.08–1.25 μM) alone or in combination for 120 h. Proliferation was measured by Calcein AM cell viability assay. Representative bliss synergy score heatmaps for three independent experiments is shown (left). Red, synergy; green, antagonism; white, no effect. The averaged dose response curves of three independent experiments are shown (right). Error bars are ± SEM. Synergy avg = average bliss synergy score. (B) KRAS mutant PDAC (10 days) and CRC organoids (5 days) were treated with RAFi (0.01–2.5 μM) and ERKi (0.04–0.63 μM) alone or in combination. Proliferation was measured by CellTiter-Glo 3D cell viability assay. Dose response curves and bliss synergy scores were calculated and represented as in (A). (C) Representative images of PDAC organoid hM1A treated with the vehicle control DMSO or RAFi (0.16 μM) or ERKi (0.04 μM) alone or in combination (left). Scale bar, 200 μm. Representative images of CRC organoid OT238 treated with DMSO or RAFi (0.31 μM) or ERKi (0.04 μM) alone or in combination (right). Scale bar, 100 μm. (D) Relative tumor volume of the NIH nude rats with implanted HPAF-II cells were treated with RAFi (20 mpk, BID) alone or in combination with the ERKi LY3214996 (LY ERKi, 10 mpk, QD) for 36 days (left). Body weight changes are shown (right). Error bars are shown as ± SEM. (E) Quantitation of blot analysis to determine levels of pRSK of tumor lysates (n = 5 animals per group). Error bars are shown as ± SEM.
Article Snippet:
Techniques: Mutagenesis, Viability Assay, Control, Quantitation Assay
Journal: Cell reports
Article Title: Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers
doi: 10.1016/j.celrep.2020.107764
Figure Lengend Snippet: KEY RESOURCES TABLE
Article Snippet:
Techniques: Virus, Mutagenesis, Recombinant, Cell Viability Assay, Viability Assay, CellTox Assay, Cytotoxicity Assay, In Situ, CRISPR, Protein Array, RNA Sequencing, Mass Spectrometry, shRNA, Sequencing, Software